This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor X [Stuart-Prower] deficiency제10인자[스튜어트-프라워]의 결핍 (제십인자스튜어트프라워결핍증)

ItemDetails
A. Classification codesICD-10: D68.2 / Special Copayment Reduction: V009
B. SynonymsStuart factor deficiency, Prower factor deficiency, Stuart-Prower factor deficiency
C. Adult onsetNot low — mild cases may first be discovered in adulthood through excessive bleeding after surgery, trauma or childbirth; acquired FX deficiency occurs in adult diseases such as amyloidosis and carcinoid tumors
1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Stuart and Prower: simultaneous discovery in two patients

Factor X (FX) was described almost simultaneously by two research groups in 1956–1957. Telfer, Denson, Howie and colleagues in Boston, USA, found that an adult patient named Rufus Stuart was deficient in a coagulation factor different from any factor known at the time, and Graham, Barrow and Hougie in Oxford, UK, independently reported a patient named Audrey Prower with a similar deficiency. The factor was named Stuart-Prower factor after the two individuals, a rare case of nomenclature in which the names of both people are preserved. The two groups later worked together and confirmed that the deficiencies of the two patients were due to the same factor.

Biochemical characterization of FX and its position in the common pathway

In the 1960s–70s, the biochemical properties of FX were elucidated one after another. It was shown that FX, a vitamin K-dependent serine protease precursor (zymogen), is activated from both the extrinsic pathway (activation by TF-FVIIa) and the intrinsic pathway (activation by the FIXa-FVIIIa complex) and functions as the first factor of the common coagulation pathway. FXa forms the prothrombinase complex together with FVa and converts prothrombin to thrombin. Because of this positional characteristic, FX deficiency shows the characteristic laboratory finding of simultaneous prolongation of PT and aPTT.

Discovery of the association between acquired FX deficiency and amyloidosis

From the 1960s, it began to be reported that FX deficiency occurs specifically in systemic amyloidosis (especially the AL type). As the unique mechanism by which amyloid fibrils selectively adsorb FX and clear it from the blood was elucidated, FX also came to be recognized as a marker of coagulation abnormalities associated with amyloidosis. Thus FX deficiency is one of the rare factor deficiencies notable for its association with specific acquired diseases (amyloidosis, carcinoid tumors) in addition to congenital forms.


2. Causes

Congenital cause: F10 gene variants

The cause of congenital FX deficiency is pathogenic variants of the F10 gene (chromosome 13q34). The F10 gene forms a cluster adjacent to the F7 (factor VII) gene on chromosome 13q34, suggesting that the two genes are paralogs that diverged from a common evolutionary ancestor. Reported variant types include missense, nonsense, splicing and frameshift variants, and studies in Iranian patient cohorts identified many homozygous variants resulting from consanguineous marriage.

Acquired causes: amyloidosis and others

Acquired causes are important in FX deficiency because FX is specifically reduced in systemic amyloidosis (AL amyloidosis). FX deficiency is observed in about 8–14% of patients with AL amyloidosis, explained by a mechanism in which amyloid fibrils adsorb FX and lower its blood concentration. In this case, FX deficiency may appear alone or together with other coagulation factor deficiencies. The mechanism of selective FX adsorption is presumed to be due to affinity of the Gla domain of FX for specific structures of amyloid fibrils. FX deficiency has also been reported in carcinoid tumors, and FX can also be reduced in vitamin K deficiency, liver failure and DIC.

Relationship with Russell viper venom (RVV)

Russell's viper venom contains a protein (RVV-X) that directly activates FX. The Russell viper venom time (RVVT) or dilute RVVT (dRVVT), which makes use of this, is used to detect lupus anticoagulant in antiphospholipid antibody syndrome, and understanding that the principle of this test is based on the FX activation pathway shows that caution is needed in interpreting RVVT prolongation in patients with FX deficiency.


3. Genetics

F10 gene structure and location

The F10 gene is located on chromosome 13q34 and consists of 8 exons. It lies adjacent to the F7 gene at the same chromosomal location, about 2.8 kb apart, supporting a common evolutionary origin of the two genes. The FX protein has a two-chain structure (light chain and heavy chain) of about 59 kDa; the light chain contains the Gla domain (γ-carboxylation site) and two EGF-like domains, and the heavy chain contains the serine protease domain. The heavy chain of activated FXa carries out the catalytic function of prothrombin cleavage in the prothrombinase complex.

Inheritance pattern and variant spectrum

Congenital FX deficiency follows an autosomal recessive mode of inheritance. Heterozygous carriers have about 50% FX activity and are mostly asymptomatic. In homozygous or compound heterozygous variants, reduced FX activity leads to clinical symptoms. A study conducted in the Isfahan region of Iran is one of the largest cohort studies to characterize the molecular features of FX deficiency in detail and made an important contribution to understanding the molecular epidemiology of congenital FX deficiency in the Middle East. Depending on the location of the variant, it is classified into two types that affect FX synthesis (quantitative deficiency, type I) or function (qualitative deficiency, type II).

Genetic aspects of combined FX and FV deficiency

Cases in which FX deficiency and FV deficiency occur together are either cases in which two independent heterozygous deficiencies happen to overlap, or cases of combined FV+FVIII deficiency due to LMAN1/MCFD2 gene variants in which FX is independently not deficient; therefore, simultaneous FV+FX deficiency has a different mechanism from combined FV+FVIII deficiency. Unlike F5, FX does not depend on endoplasmic reticulum–Golgi transport proteins and is therefore unrelated to the LMAN1/MCFD2 pathway. When FX deficiency is suspected, it is important to also measure levels of other factors such as FV, FII and FVII to differentiate combined deficiencies.


4. General epidemiology

Prevalence and geographic distribution

The worldwide prevalence of congenital FX deficiency is estimated at about 1/500,000–1/1,000,000, making it relatively well known among rare coagulation factor deficiencies, second to FVII deficiency. In EN-RBD registry data, FX deficiency accounts for about 8–10% of all rare coagulation factor deficiencies. A high frequency due to consanguineous marriage has been reported in Iran, southern Italy and parts of the Middle East. In particular, large study data from Iran have contributed greatly to understanding the clinical epidemiology of FX deficiency worldwide.

Sex and age characteristics

Because inheritance is autosomal recessive, males and females are equally affected. Severe deficiency (FX <1%) presents early from the neonatal period with umbilical cord bleeding and intracranial hemorrhage. Patients with mild and moderate deficiency may first be diagnosed in adulthood through excessive bleeding after surgery, trauma or childbirth. Acquired FX deficiency (associated with amyloidosis) occurs mainly in adulthood (age 50 and older) and is discovered through a bleeding tendency of unknown cause or abnormal coagulation test results.

Special features of acquired FX deficiency: amyloidosis

FX deficiency in AL amyloidosis is a clinically very important issue. As one of the causes of bleeding complications occurring during pre-transplant chemotherapy or stem cell transplantation (SCT), FX deficiency must be checked for before treatment. The degree of FX deficiency in AL amyloidosis is roughly proportional to the amount of amyloid deposition, and FX levels sometimes recover when treatment (chemotherapy, stem cell transplantation) reduces the amyloid burden. FX deficiency in carcinoid tumors is explained by serotonin-mediated platelet activation or cytokine-dependent impairment of synthesis, but the mechanism has not been fully elucidated.


5. Pathophysiology

Position and activation of FX in the common pathway

FX is activated to FXa by two pathways, the extrinsic pathway (TF-FVIIa complex) and the intrinsic pathway (FIXa-FVIIIa complex, tenase complex), and functions as the first factor of the common coagulation pathway. FXa, together with FVa, Ca²⁺ and phospholipid, forms the prothrombinase complex, which converts prothrombin to thrombin. FXa itself has only weak prothrombin-cleaving activity, but in the complex bound to FVa and a phospholipid surface, the rate of prothrombin conversion increases about 300,000-fold or more compared with FXa alone. This dramatic amplification is the core of the hemostatic mechanism that responds rapidly to external bleeding stimuli.

Pathophysiology of FX deficiency

When FX is deficient, entry into the common pathway is blocked from both coagulation pathways (extrinsic and intrinsic). As a result, the prothrombinase complex cannot form sufficiently, and thrombin generation is severely reduced. At FX activity below 1%, spontaneous bleeding (intracranial hemorrhage, hemarthrosis, umbilical cord bleeding) occurs. Because FX is the first factor of the common pathway, FX deficiency prolongs both the PT, which reflects the extrinsic pathway, and the aPTT, which reflects the intrinsic pathway. In this respect, the laboratory pattern of FX deficiency is similar to that of FII and FV deficiency.

Mechanism of acquired FX deficiency in amyloidosis

The mechanism by which FX is specifically reduced in AL amyloidosis is that the Gla domain of FX binds with high affinity to specific structures of amyloid fibrils (composed of misfolded immunoglobulin light chain), so that circulating FX is selectively adsorbed and cleared in amyloid-deposited tissues (mainly liver and spleen). A characteristic of this mechanism is that it shows higher affinity for FX than for other Gla domain-containing factors (FII, FVII, FIX). Therefore, when coagulation abnormalities are found in amyloidosis, isolated FX deficiency often occurs first, and FX measurement is essential in the coagulation assessment of patients with AL amyloidosis.


6. Symptoms

Symptoms of severe deficiency (FX <1%)

In severe deficiency with FX activity below 1%, serious bleeding symptoms occur from early after birth. The most typical initial symptom is umbilical cord bleeding, followed by intracranial hemorrhage (ICH), hemarthrosis and intramuscular hematomas. Intracranial hemorrhage is reported to occur in about 10–15% of all patients with FX deficiency and is fatal. Gastrointestinal bleeding, epistaxis and oral mucosal bleeding also occur. In female patients, menorrhagia, excessive postpartum bleeding and bleeding complications during pregnancy are prominent. Urinary tract bleeding (hematuria) is also a characteristic symptom of severe deficiency that is not uncommon.

Symptoms of moderate and mild deficiency

In moderate deficiency with FX activity of 1–10%, excessive bleeding after surgery, trauma, dental procedures and childbirth is the main clinical symptom. Nosebleeds, gum bleeding and subcutaneous hematomas may recur. In mild deficiency with FX activity of 10–50%, patients may live without everyday bleeding and be discovered incidentally when preoperative testing shows prolongation of both PT and aPTT. In an FX deficiency cohort study from the Isfahan region of Iran, hemarthrosis and intracranial hemorrhage were reported as the most common severe bleeding complications.

Symptoms of acquired FX deficiency (associated with amyloidosis)

When FX deficiency develops in patients with AL amyloidosis, spontaneous bleeding or excessive bleeding even with minor trauma occurs. In particular, skin bleeding (periorbital ecchymosis, a characteristic finding called 'raccoon eyes'), gastrointestinal bleeding and urinary tract bleeding appear. In this case, the systemic symptoms of amyloidosis (heart failure, nephrotic syndrome, peripheral neuropathy) are also present, so the clinical picture is complex. Fragility of skin blood vessels (amyloid vascular deposition) is an additional factor that worsens the bleeding tendency.


7. Signs

Physical examination findings

Physical examination findings in patients with FX deficiency vary with the severity of the deficiency and whether it is congenital or acquired. In severe congenital deficiency, extensive ecchymoses, mucosal bleeding, joint swelling and neurological sequelae after intracranial hemorrhage are observed. In acquired FX deficiency (AL amyloidosis), the characteristic findings of amyloidosis are observed: macroglossia, periorbital ecchymosis ('raccoon eyes'), supraclavicular fat pads (shoulder pad sign) and lower limb edema (when nephrotic syndrome is present). In amyloidosis, skin blood vessels are so fragile that subcutaneous bleeding occurs with only minor physical stimuli.

Laboratory abnormalities

The most characteristic laboratory finding of FX deficiency is simultaneous prolongation of PT and aPTT. TT and fibrinogen are normal, distinguishing it from FI deficiency. Because it is vitamin K-dependent, differentiation from vitamin K deficiency or warfarin use is needed, but in congenital FX deficiency, FVII, FIX and FII are normal. In acquired FX deficiency associated with AL amyloidosis, isolated FX reduction or combined reduction with other vitamin K-dependent factors may be observed. On mixing studies, correction of PT and aPTT with normal plasma suggests deficiency, while lack of correction suggests an inhibitor or lupus anticoagulant.

Imaging and pathology findings

In FX deficiency associated with amyloidosis, hepatomegaly and splenomegaly are often observed on abdominal ultrasound or CT, and ventricular wall thickening (diastolic dysfunction) is often confirmed on echocardiography. Cardiac MRI may show characteristic late gadolinium enhancement due to amyloid deposition. Confirmation of the apple-green birefringence characteristic of amyloid on Congo red staining of bone biopsy or fat aspiration biopsy is key to the diagnosis of AL amyloidosis.


8. Screening

Differentiating the pattern of simultaneous PT and aPTT prolongation

Screening for FX deficiency starts from a pattern of simultaneous prolongation of PT and aPTT with normal TT and fibrinogen. To differentiate simultaneous PT and aPTT prolongation, vitamin K status (if FVII, FIX, FX and FII are all reduced, vitamin K deficiency or warfarin), liver failure (multiple factor reduction, albumin and bilirubin abnormalities) and DIC (thrombocytopenia, elevated D-dimer) are excluded first. After exclusion, FX, FII and FV deficiency and fibrinogen abnormalities are considered sequentially as the remaining causes. FX deficiency can be distinguished from vitamin K deficiency by confirming that FII, FVII and FIX levels are normal.

Specific FX factor testing and severity classification

If PT and aPTT are corrected with normal plasma on the mixing study, FX-specific factor activity is measured. FX activity is measured by PT- or aPTT-based clotting assays using FX-deficient substrate plasma. Comparing FX antigen levels with activity distinguishes qualitative deficiency (CRM+, normal antigen but reduced activity) from quantitative deficiency (CRM-, both antigen and activity reduced). Severity classification: <1% severe, 1–10% moderate, 10–50% mild.

Screening for acquired FX deficiency associated with amyloidosis

When coagulation abnormalities are found in patients with AL amyloidosis, it is important to screen for FX deficiency. If coagulation testing shows isolated FX reduction or combined reduction of FX and FV, amyloidosis is strongly suspected. In patients suspected of amyloidosis, serum protein electrophoresis (SPEP), immunoelectrophoresis (IEP), serum free light chain (FLC) measurement and bone marrow biopsy are used for diagnosis. After confirmation, monitoring FX levels during treatment can also indirectly assess whether the amyloid burden has decreased.


9. Diagnosis

Diagnostic criteria

Congenital FX deficiency is confirmed in the following order: ① simultaneous prolongation of PT and aPTT, ② reduced FX activity on FX-specific factor testing (severe <1%, moderate 1–10%, mild 10–50%), ③ normal vitamin K-dependent factors (FVII, FIX, FII), ④ exclusion of acquired causes such as vitamin K deficiency, warfarin, liver failure and DIC, ⑤ identification of a pathogenic F10 gene variant. Diagnosis of acquired FX deficiency is made together with diagnosis of the underlying disease (amyloidosis, carcinoid tumor).

Differential diagnosis

Differential diagnosis of simultaneous PT and aPTT prolongation: ① vitamin K deficiency or warfarin (FVII, FIX, FX and FII all reduced), ② FII deficiency (FX normal, FII reduced), ③ FV deficiency (FX normal, FV reduced, not vitamin K-dependent), ④ fibrinogen deficiency (TT prolonged, fibrinogen reduced), ⑤ DIC (thrombocytopenia, elevated D-dimer), ⑥ combined factor deficiency (combined FX+FV or FX+FII deficiency rarely possible). Isolated prolongation of the Russell viper venom test (RVVT) is a finding strongly suggestive of FX deficiency, but lupus anticoagulant must be excluded.

Genetic counseling

The parents of confirmed patients are heterozygous carriers, and FX activity testing is recommended for them. Screening is also performed for siblings. In patients planning pregnancy, the possibility of preimplantation genetic diagnosis or prenatal diagnosis is discussed. In communities with consanguineous marriage, carrier identification contributes to preventing the birth of newborns with severe deficiency. In patients with acquired FX deficiency, the genetic background of the underlying disease is evaluated (AL amyloidosis arises from plasma cell dyscrasias; differentiation from some hereditary amyloidoses).


10. Treatment

Prothrombin complex concentrate (PCC): standard treatment

In the treatment of congenital FX deficiency, prothrombin complex concentrate (PCC) is the most effective treatment. Because PCC contains vitamin K-dependent coagulation factors (FII, FVII, FIX, FX), it is used directly for FX replacement. Both 3-factor PCC and 4-factor PCC contain FX. The half-life of FX is relatively long at about 40–45 hours, which has the advantage that FX levels are maintained stably after PCC administration. Target FX levels of 25–30% or higher are recommended for acute bleeding and 30% or higher during surgery, and for prophylactic administration a trough level of 10–15% or higher is targeted.

Fresh frozen plasma (FFP)

When PCC is not available, fresh frozen plasma (FFP) is an alternative. FFP contains all coagulation factors and is used for FX replacement, but large volumes are needed to sufficiently correct FX, with a risk of volume overload. In adults, 15–20 mL/kg of FFP is needed to raise FX by 10–15%. Given the long half-life of FX, the interval between FFP doses can be extended, making it more practical than in the treatment of FV deficiency.

Treatment of acquired FX deficiency (amyloidosis)

The fundamental treatment of acquired FX deficiency associated with AL amyloidosis is to treat the underlying plasma cell dyscrasia to reduce the amyloid burden. When hematologic remission is achieved with chemotherapy (bortezomib-based regimens, lenalidomide-based regimens) or autologous stem cell transplantation (ASCT), amyloid fibrils are gradually resorbed and FX levels can recover. PCC or FFP is given to prevent bleeding during treatment, and FX levels are maintained at target levels before and after surgery (including transplantation). In amyloidosis, use of tranexamic acid can provide an additional hemostatic effect by inhibiting fibrinolysis, but the risk of thrombosis in severe amyloidosis must be considered.


11. Prognosis

Prognosis of severe congenital deficiency

In severe FX deficiency (FX <1%), if diagnosis and prophylactic treatment are not provided before intracranial hemorrhage occurs, the risk of death or serious neurological sequelae is high. When a prophylactic PCC regimen is in place, intracranial hemorrhage can be prevented and long-term survival improves. Because the half-life of FX (40–45 hours) is relatively long, the PCC prophylaxis interval can be kept at about 1–2 times a week, making management easier in some respects than for other factor deficiencies. When hemarthrosis recurs, joint damage similar to hemophilic arthropathy may accumulate.

Prognosis of mild and moderate deficiency

Patients with FX activity of 1–50% can maintain a quality of life nearly equal to that of the general population with appropriate preoperative management and a plan for PCC administration in risk situations. In female patients, monitoring FX levels during pregnancy and planning PCC supply before delivery can minimize obstetric complications. Clinical development of recombinant FX is currently under way, opening the possibility of safe FX replacement therapy without the risk of viral transmission.

Prognosis of acquired FX deficiency (amyloidosis)

The prognosis of FX deficiency associated with AL amyloidosis depends on the treatment response of the underlying plasma cell disorder. When hematologic remission (complete remission or stringent complete remission) is achieved, FX levels have been reported to recover with a marked reduction in bleeding risk. However, when there is no response to treatment, FX deficiency persists, and morbidity and mortality from bleeding are high. Considering that the prognosis of AL amyloidosis itself varies greatly depending on cardiac and renal involvement, FX deficiency is recognized as one of the poor prognostic factors.


12. Prevention

Prophylactic PCC administration plan

In severe FX deficiency (FX <1%), regular prophylactic PCC administration is recommended to prevent spontaneous bleeding, especially intracranial hemorrhage. Because the half-life of FX (40–45 hours) is relatively long, PCC given 1–2 times a week can maintain the FX trough level at 10–15% or higher. This is a favorable condition that allows less frequent dosing than in the treatment of FV or FVII deficiency. When PCC is administered, the risk of thrombotic complications (deep vein thrombosis, pulmonary embolism) should be monitored, and periodic clinical evaluation is needed, especially for those receiving long-term prophylaxis.

Preoperative and postoperative preparation

FX activity is measured before surgery, and a PCC dosing plan is established to achieve the target FX level according to surgical risk (30% or higher for major surgery, 15–20% or higher for minor surgery). Because the half-life of FX is long, FX levels can be maintained for at least 24–48 hours after preoperative administration. Taking into account the postoperative thrombotic risk (especially when PCC is used for FX deficiency), the need for postoperative antithrombotic prophylaxis is judged individually. Real-time coagulation monitoring using intraoperative viscoelastic coagulation tests (ROTEM, TEG) is recommended.

Genetic counseling and prevention of acquired FX deficiency

Asymptomatic deficient individuals are identified early through FX activity screening and genetic counseling for the families of patients with congenital FX deficiency. In communities with consanguineous marriage, offering FX deficiency carrier testing can prevent the birth of newborns with severe deficiency. The key to preventing acquired FX deficiency is early diagnosis and treatment of AL amyloidosis. In patients with an unexplained bleeding tendency or simultaneous PT and aPTT prolongation, it is important to actively investigate the possibility of amyloidosis (serum free light chain test, bone marrow biopsy) along with measuring FX levels.


13. References

  1. Peyvandi F, Mannucci PM, Lak M, et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol. 1998;102(2):626-628.
  2. Marchetti G, Castaman G, Pinotti M, et al. Molecular bases of CRM-positive factor X deficiency: a frequent mutation (Ser334Pro) occurring in the catalytic domain. Br J Haematol. 1993;85(3):521-527.
  3. Girolami A, Cosi E, Girolami B, et al. Factor X deficiencies of various types: a classification and a critical review of the literature. Acta Haematol. 2016;135(3):148-158.
  4. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885-1887.
  5. Ditto B, Rybicki L, Ball K, et al. Serial factor X levels: a useful tool in the management of amyloidosis-associated factor X deficiency. Blood. 2019;134(Suppl 1):5697.
  6. Telfer TP, Denson KW, Wright DR. A "new" coagulation defect. Br J Haematol. 1956;2(3):308-316.
  7. Graham JB, Barrow EM, Hougie C. Stuart clotting defect. II. Genetic aspects of a "new" hemorrhagic state. J Clin Invest. 1957;36(3):497-503.
  8. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  9. Uprichard J, Perry DJ. Factor X deficiency. Blood Rev. 2002;16(2):97-110.
  10. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders. Br J Haematol. 2014;167(3):304-326.
  11. Lak M, Sharifian RA, Peyvandi F, Mannucci PM. Symptoms of inherited factor X deficiency in 16 Iranian patients. Br J Haematol. 1998;103(4):1067-1069.
  12. Herrmann FH, Wulff K, Auerswald G, et al. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia. 2009;15(1):267-280.